These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3539499)

  • 1. From experimental to clinical attempts in immunorestoration with bestatin and zinc.
    Mathé G; Blazsek I; Canon C; Gil-Delgado M; Misset JL
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):241-52. PubMed ID: 3539499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do tuftsin and bestatin constitute a biopharmacological immunoregulatory system?
    Mathé G
    Cancer Detect Prev Suppl; 1987; 1():445-55. PubMed ID: 3319151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation.
    Ino K; Bierman PJ; Varney ML; Heimann DG; Kuszynski CA; Walker SA; Talmadge JE
    Cancer Immunol Immunother; 1996 Dec; 43(4):206-12. PubMed ID: 9003465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin.
    Noma T; Klein B; Cupissol D; Yata J; Serrou B
    Int J Immunopharmacol; 1984; 6(2):87-92. PubMed ID: 6429060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bestatin, an inhibitor of aminopeptidase B, suppresses the proliferation and differentiation of human B-cells in vitro.
    Morikawa K; Morikawa S; Nakano A; Oseko F
    Int J Immunopharmacol; 1989; 11(8):905-13. PubMed ID: 2613395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceleration of age-associated immune decline and mortality by early repeated administration of bestatin to C57BL/6 mice.
    Bruley-Rosset M; Payelle B; Rappaport H
    J Biol Response Mod; 1986 Apr; 5(2):176-90. PubMed ID: 3488372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulatory effects of bestatin on human B-cell colony formation.
    Otsuka T; Okamura S; Ohhara N; Harada M; Hayashi S; Yamaga S; Omori F; Niho Y
    Int J Immunopharmacol; 1988; 10(5):587-91. PubMed ID: 3263340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
    Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
    Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
    Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
    Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bestatin treatment and the peripheral lymphocyte population in cancer patients.
    Blomgren H; Strender LE; Edsmyr F
    Recent Results Cancer Res; 1980; 75():133-8. PubMed ID: 7232824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patients.
    Mathé G; Misset JL; Gil-Delgado M; Musset M; Reizenstein P; Canon C
    Biomed Pharmacother; 1986; 40(10):383-5. PubMed ID: 3495300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
    Schorlemmer HU; Bosslet K; Sedlacek HH
    Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells.
    Müller WE; Schuster DK; Zahn RK; Maidhof A; Leyhausen G; Falke D; Koren R; Umezawa H
    Int J Immunopharmacol; 1982; 4(5):393-400. PubMed ID: 6982243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of bestatin on the growth of human lymphocytes.
    Ino K; Isobe K; Goto S; Nakashima I; Tomoda Y
    Immunopharmacology; 1992; 23(3):163-71. PubMed ID: 1500283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of immunodeficiency in aged mice by levamisole and bestatin administration.
    Bruley-Rosset M; Florentin I; Kiger N; Schulz JI; Mathé G
    Recent Results Cancer Res; 1980; 75():139-46. PubMed ID: 7232825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bestatin therapy of patients with atopic dermatitis.
    Thestrup-Pedersen K; Cramers M; Kongsholm H; Zachariae H
    Acta Derm Venereol; 1983; 63(6):549-52. PubMed ID: 6198850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.